Paper41550643
Assay development and screening of inhibitors targeting the SARS-CoV-2 2'-O-methyltransferase NSP16.
Cao M and 9 others. Pharm Sci Adv, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Assay development and screening of inhibitors targeting the SARS-CoV-2 2'-O-methyltransferase NSP16. Papers, record 41550643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41550643
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Assay development and screening of inhibitors targeting the SARS-CoV-2 2'-O-methyltransferase NSP16.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R41 AI177149 | NIAID NIH HHS | United States | R41AI177149 | PubMed | NIH RePORTER |
| R01 AI161845 | NIAID NIH HHS | United States | R01AI161845 | PubMed and NIH | NIH RePORTER |
| R01 AI175435 | NIAID NIH HHS | United States | R01AI175435 | PubMed | NIH RePORTER |
| R56 AI131669 | NIAID NIH HHS | United States | R01AI131669 | PubMed and NIH | NIH RePORTER |
| R01 AI131669 | NIAID NIH HHS | United States | R01AI131669 | PubMed and NIH | NIH RePORTER |
| R21 AI158176 | NIAID NIH HHS | United States | R21AI158176 | PubMed | NIH RePORTER |
| R35 GM149230 | NIGMS NIH HHS | United States | R35GM149230 | PubMed and NIH | NIH RePORTER |
| R56AI131669 | NIH | NIH RePORTER |
References55
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32007145 | Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. | Lancet | 2020 | https://conductscience.org/library/papers/32007145 | PubMed |
| 2 | 15140959 | Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. | J Virol | 2004 | https://conductscience.org/library/papers/15140959 | PubMed |
| 3 | 34762019 | Structural screening into the recognition of a potent inhibitor against non-structural protein 16: a molecular simulation to inhibit SARS-CoV-2 infection. | J Biomol Struct Dyn | 2022 | https://conductscience.org/library/papers/34762019 | PubMed |
| 4 | 34096718 | OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space. | J Chem Theory Comput | 2021 | https://conductscience.org/library/papers/34096718 | PubMed |
| 5 | 32571880 | Structural and functional conservation of the programmed -1 ribosomal frameshift signal of SARS coronavirus 2 (SARS-CoV-2). | J Biol Chem | 2020 | https://conductscience.org/library/papers/32571880 | PubMed |
| 6 | 37429335 | Methyl gallate: Review of pharmacological activity. | Pharmacol Res | 2023 | https://conductscience.org/library/papers/37429335 | PubMed |
| 7 | 36040262 | Crystal structure of SARS-CoV-2 nsp10-nsp16 in complex with small molecule inhibitors, SS148 and WZ16. | Protein Sci | 2022 | https://conductscience.org/library/papers/36040262 | PubMed |
| 8 | 34751829 | Molecular docking and pharmacokinetic studies of phytocompounds from Nigerian Medicinal Plants as promising inhibitory agents against SARS-CoV-2 methyltransferase (nsp16). | J Genet Eng Biotechnol | 2021 | https://conductscience.org/library/papers/34751829 | PubMed |
| 9 | 16828802 | RNA recognition and cleavage by the SARS coronavirus endoribonuclease. | J Mol Biol | 2006 | https://conductscience.org/library/papers/16828802 | PubMed |
| 10 | 23602469 | Viral precursor polyproteins: keys of regulation from replication to maturation. | Curr Opin Virol | 2013 | https://conductscience.org/library/papers/23602469 | PubMed |
| 11 | 28031370 | Binding of the Methyl Donor S-Adenosyl-l-Methionine to Middle East Respiratory Syndrome Coronavirus 2'-O-Methyltransferase nsp16 Promotes Recruitment of the Allosteric Activator nsp10. | J Virol | 2017 | https://conductscience.org/library/papers/28031370 | PubMed |
| 12 | 32397643 | Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA. | Viruses | 2020 | https://conductscience.org/library/papers/32397643 | PubMed |
| 13 | 39325663 | The AXL inhibitor bemcentinib overcomes microenvironment-mediated resistance to pioglitazone in acute myeloid leukemia. | FEBS J | 2025 | https://conductscience.org/library/papers/39325663 | PubMed |
| 14 | 20463816 | Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. | PLoS Pathog | 2010 | https://conductscience.org/library/papers/20463816 | PubMed |
| 15 | 35225672 | Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning? | J Virol | 2022 | https://conductscience.org/library/papers/35225672 | PubMed |
| 16 | 33919870 | Molecular Simulation-Based Investigation of Highly Potent Natural Products to Abrogate Formation of the nsp10-nsp16 Complex of SARS-CoV-2. | Biomolecules | 2021 | https://conductscience.org/library/papers/33919870 | PubMed |
| 17 | 37060263 | A universal fluorescence polarization high throughput screening assay to target the SAM-binding sites of SARS-CoV-2 and other viral methyltransferases. | Emerg Microbes Infect | 2023 | https://conductscience.org/library/papers/37060263 | PubMed |
| 18 | 35259661 | Design and various in silico studies of the novel curcumin derivatives as potential candidates against COVID-19 -associated main enzymes. | Comput Biol Chem | 2022 | https://conductscience.org/library/papers/35259661 | PubMed |
| 19 | 15220459 | Human coronavirus 229E nonstructural protein 13: characterization of duplex-unwinding, nucleoside triphosphatase, and RNA 5'-triphosphatase activities. | J Virol | 2004 | https://conductscience.org/library/papers/15220459 | PubMed |
| 20 | 33317409 | Multitarget in silico studies of Ocimum menthiifolium, family Lamiaceae against SARS-CoV-2 supported by molecular dynamics simulation. | J Biomol Struct Dyn | 2022 | https://conductscience.org/library/papers/33317409 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42921030 | Structure-Based Design of New Nonpeptidic Covalent Mpro Inhibitors against SARS-CoV‑2 and Omicron Variants. | ACS Bio Med Chem Au | 2026 | https://conductscience.org/library/papers/42921030 | PubMed |
| 42357309 | Targeting SARS-CoV-2 Non-Structural Proteins: A Blueprint for Next-Generation Small-Molecule Coronavirus Antivirals. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42357309 | PubMed |
| 42048414 | Selective Targeting of Protein Arginine Methyltransferase 1 (PRMT1) Mutant Activity by a Small Molecule Activation Strategy. | ACS Chem Biol | 2026 | https://conductscience.org/library/papers/42048414 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CAP1 | 10487 | PubTator's text mining | https://conductscience.org/library/genes/10487 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41550643
GET https://conductscience.org/api/papers/v1/41550643/references?page=2